Suppr超能文献

利用意大利全科医生数据库识别严重潜在药物相互作用。

Identification of severe potential drug-drug interactions using an Italian general-practitioner database.

作者信息

Magro L, Conforti A, Del Zotti F, Leone R, Iorio M L, Meneghelli I, Massignani D, Visonà E, Moretti U

机构信息

Clinical Pharmacology Unit, University of Verona, Verona, Italy.

出版信息

Eur J Clin Pharmacol. 2008 Mar;64(3):303-9. doi: 10.1007/s00228-007-0394-1. Epub 2007 Nov 9.

Abstract

OBJECTIVE

To analyze prescriptions in a general-practitioner database over 1 year to determine the frequency, the characteristics, and the monitoring of the severe potential drug-drug interactions (DDIs).

METHODS

We retrospectively analyzed the clinical records from 16 general practitioners in the Veneto region, an area in northern Italy. The study covered the period from January 1 to December 31, 2004. We selected all severe and well-documented interactions according to the book Drug Interaction Facts by David S. Tatro (Facts and Comparisons, St. Louis, MO, 2006). We grouped severe potential DDIs according to their specific potential risk, and for the most frequently interacting drug pairs, we investigated whether some specific tests had been prescribed by physicians for safety monitoring.

RESULTS

During the study period, 16,037 patients (55% female) with at least one drug prescription were recorded, and a total of 185,704 prescriptions relating to 1,020 different drugs were analyzed. Ramipril was the most frequently prescribed drug followed by acetylsalicylic acid and atorvastatin. The final number of different types of severe potential DDIs was 119, which occurred 1,037 times in 758 patients (4.7% of the total number of patients). More than 80% of drugs involved in severe potential DDIs were cardiovascular drugs. Digoxin was the most frequently involved drug. Electrolyte disturbances, increase in serum digoxin levels, risk of hemorrhage, severe myopathy or rhabdomyolysis, and cardiac arrhythmias were the most commonly implicated potential risks. When considering patients using digoxin with loop or thiazide diuretics for more than 5 months, 72% had at least one test to monitor potential digoxin toxicity, whereas 28% had no tests. Sixty-four percent of patients using digoxin with amiodarone, verapamil, or propafenone had an ECG and/or digoxin monitoring, and 36% of them did not have any tests.

CONCLUSIONS

The present study revealed that, in a group of Italian general practitioners, the risks of severe potential drug interactions are relatively low and the drugs concerned are few. Analyses of specific tests showed that physicians are generally aware of the potential risks caused by digoxin drug associations. However not all patients were closely monitored and this should be improved.

摘要

目的

分析一个全科医生数据库中超过1年的处方,以确定严重潜在药物相互作用(DDIs)的发生频率、特征及监测情况。

方法

我们回顾性分析了意大利北部威尼托地区16名全科医生的临床记录。研究涵盖2004年1月1日至12月31日期间。我们根据David S. Tatro所著的《药物相互作用事实》(Facts and Comparisons,密苏里州圣路易斯,2006年)一书,选取了所有严重且记录充分的相互作用。我们根据其特定潜在风险对严重潜在DDIs进行分组,对于最常相互作用的药物对,我们调查了医生是否开具了一些特定检查用于安全监测。

结果

在研究期间,记录了16,037名至少有一张药物处方的患者(55%为女性),共分析了与1,020种不同药物相关的185,704张处方。雷米普利是最常开具的药物,其次是乙酰水杨酸和阿托伐他汀。不同类型严重潜在DDIs的最终数量为119种,在758名患者中发生了1,037次(占患者总数的4.7%)。涉及严重潜在DDIs的药物中,超过80%为心血管药物。地高辛是最常涉及的药物。电解质紊乱、血清地高辛水平升高、出血风险、严重肌病或横纹肌溶解以及心律失常是最常涉及的潜在风险。在考虑使用地高辛与袢利尿剂或噻嗪类利尿剂超过5个月的患者时,72%的患者至少进行了一项监测地高辛潜在毒性的检查,而28%的患者未进行检查。使用地高辛与胺碘酮、维拉帕米或普罗帕酮的患者中,64%进行了心电图和/或地高辛监测,36%的患者未进行任何检查。

结论

本研究表明,在一组意大利全科医生中,严重潜在药物相互作用的风险相对较低,且涉及的药物较少。对特定检查的分析表明,医生通常意识到地高辛药物联合使用所带来的潜在风险。然而,并非所有患者都得到了密切监测,这一点应加以改善。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验